458 related articles for article (PubMed ID: 31200836)
21. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.
Trinh VQ; Sirois J; Benzerdjeb N; Mansoori BK; Grosset AA; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Ladouceur M; Fradet Y; Saad F; Trudel D
Prostate; 2018 Jul; 78(10):697-706. PubMed ID: 29603326
[TBL] [Abstract][Full Text] [Related]
22. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
24. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
Seyrek N; Hollemans E; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Bangma CH; Rietbergen J; Roobol MJ; Schoots IG; van Leenders GJLH
Histopathology; 2022 Feb; 80(3):558-565. PubMed ID: 34706119
[TBL] [Abstract][Full Text] [Related]
25. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
[TBL] [Abstract][Full Text] [Related]
27. Associations Between Intraductal Prostate Cancer and Metastases Following Radical Prostatectomy in Men With Prostate Cancer in the Veterans Affairs Database.
Nelson TJ; Kumar A; Nalawade V; Nonato T; Shabaik A; Roma A; Rose BS; McKay RR
Clin Genitourin Cancer; 2023 Aug; 21(4):452-458. PubMed ID: 37095044
[TBL] [Abstract][Full Text] [Related]
28. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
Dietrich D; Hasinger O; Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Wernert N; Perner S; Freedland SJ; Corman JM; Ittmann MM; Lark AL; Madden JF; Hartmann A; Schatz P; Kristiansen G
J Mol Diagn; 2013 Mar; 15(2):270-9. PubMed ID: 23266319
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of cribriform size, percentage, and intraductal carcinoma in Gleason score 7 prostate cancer with cribriform Gleason pattern 4.
Chen Z; Pham H; Abreu A; Amin MB; Sherrod AE; Xiao GQ; Aron M
Hum Pathol; 2021 Dec; 118():18-29. PubMed ID: 34543668
[TBL] [Abstract][Full Text] [Related]
30. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
31. Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
Seyrek N; Hollemans E; Andrinopoulou ER; Osanto S; Pelger RCM; van der Poel HG; Bekers E; Remmers S; Schoots IG; van Leenders GJLH
Virchows Arch; 2022 Jun; 480(6):1149-1157. PubMed ID: 35157140
[TBL] [Abstract][Full Text] [Related]
32. Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.
Currin S; Flood TA; Krishna S; Ansari A; McInnes MDF; Schieda N
J Magn Reson Imaging; 2019 Jul; 50(1):279-287. PubMed ID: 30585372
[TBL] [Abstract][Full Text] [Related]
33. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.
Trinh VQ; Benzerdjeb N; Chagnon-Monarque S; Dionne N; Delouya G; Kougioumoutzakis A; Sirois J; Albadine R; Latour M; Mes-Masson AM; Hovington H; Bergeron A; Zorn KC; Fradet Y; Saad F; Taussky D; Trudel D
Radiat Oncol; 2019 Apr; 14(1):60. PubMed ID: 31018850
[TBL] [Abstract][Full Text] [Related]
34. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
Kweldam CF; Kümmerlin IP; Nieboer D; Steyerberg EW; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2017 Aug; 30(8):1126-1132. PubMed ID: 28530220
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
[TBL] [Abstract][Full Text] [Related]
36. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
37. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
38. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate.
Lone Z; Benidir T; Rainey M; Nair M; Davicioni E; Gibb EA; Williamson S; Gupta S; Chaim Ornstein M; Tendulkar R; Weight C; Nguyen JK; Klein EA; Mian OY
Eur Urol Focus; 2022 Nov; 8(6):1575-1582. PubMed ID: 35662504
[TBL] [Abstract][Full Text] [Related]
39. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
40. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
